Mumbai headquartered Glenmark pharmaceuticals has annpunced that the US affiliate of the company Glenmark Generics has got final sanction from US Food and Drug Administration (USFDA) to sell Ranitidine Hydrochloride on prescription basis.

The approval has been granted for 150 mg and 300 mg dosage of the drug.

According to the sources, Ranitidine is indicated for prevention and developing of ulcer in the stomach. The drug also reduces stomach pain, diarrhea, and loss of appetite that ulcers can cause.

Recently, the company`s US arm has started distribution of Morphine Sulfate oral concentrate solution, which is company`s fifth product offering in the arena of pain management in the US market through a licensing pact with a US-based pharmaceutical development conglomerate.

The sources further revealed that the company has also gained full marketing rights in the US for marketing Azathioprine tablets in the strength of 50mg. The drug is indicated for the prevention of rejection in renal homotransplantations (kidney transplant), and also for reducing signs and symptoms of active rheumatoid arthritis.

Stock of Glenmark Pharma ended the day at Rs 307, down 3.56 percent on National Stock Exchange (NSE). The total volume of shares traded at NSE was 282,106.